5(S)-HETrE is produced by the action of 5-LO when mead acid is the substrate. There are no literature reports of the biological activity or further metabolic fate of 5(S)-HETrE.

A potential cytochrome P450 metabolite of N-arachidonoyl taurine that may activate TRPV1 and TRPV4.

An epoxygenase pathway product produced from EPA by CYP450 both in vitro and in vivo; its effects of remain to be determined.

A DHA epoxygenase metabolite detected in rat brain and spinal cord, as well as human serum, that acts as a substrate for sEH (Km = 5.1 µM); demonstrates antihyperalgesic activity in inflammatory and neuropathic pain models and potently inhibits angiogenesis and tumor growth in in vitro assays.

A major urinary metabolite of PGE2 that is excreted in guinea pig urine at a concentration range of 1.34-2.74.

Key urinary metabolite of PGD2; represents approximately 1% and 4% of the infused radiolabeled dose in monkeys and humans, respectively.

An aspirin-triggered lipoxin that inhibits LTB4-induced chemotaxis, adherence, and transmigration of the neutrophils with twice the potency of LXA4 demonstrating activity in the nM range.

A bioactive macrolide derived from sponges that binds monomeric actin, preventing actin polymerization both in vitro (Kd = 0.2 μM) and in cells (0.5 μM).

The racemic version of a CYP450 metabolite of arachidonic acid that dose-dependently stimulates vasodilation of the rabbit kidney.

(±)12-HpETE is one of the six monohydroperoxy fatty acids produced by the non-enzymatic oxidation of arachidonic acid (Item No. 90010) and consists of an equal mixture of the R and S isomers. Reduction of the hydroperoxide yields the more stable hydroxyl fatty acid (±)12-HETE (Item…

(±)8-HETE is one of the six monohydroxy fatty acids produced by the non-enzymatic oxidation of arachidonic acid.

A purified enantiomer of (±)9-HETE resulting from non-enzymatic oxidation of arachidonic acid.

A potent, selective inhibitor of PKG (in vitro IC50 = 234 nM); cell-permeable and often used in intact cells to assess the role of PKG in signaling.

A major CYP450 metabolite of arachidonic acid that is released from the kidney in response to angiotensin II; a potent vasodilator of renal preglomerular vessels; blocks 20-HETE-induced vasoconstriction of renal arterioles at 1 µM.

(±)9-HETE is one of the six monohydroxy fatty acids produced by the non-enzymatic oxidation of arachidonic acid. The individual R and S isomers of racemic HETEs have been separated and identified using chiral phase HPLC. The racemic HETEs have been quantified as an index of lipid…

(±)5-HETE is one of the six monohydroxy fatty acids produced by the non-enzymatic oxidation of arachidonic acid. It contains equal amounts of 5(S)-HETE and 5(R)-HETE. (±)5-HETE induces the aggregation of isolated neutrophils with an IC₅₀ value of 200 nM.

A DHA epoxygenase metabolite found in rat brain and spinal cord that acts as a preferred substrate for sEH (Km = 3.2 µM); demonstrates antihyperalgesic activity in inflammatory and neuropathic pain models and potently inhibits angiogenesis and tumor growth in in vitro assays.

A DHA-derived product first identified in mouse inflammatory exudates; reduces neutrophil infiltration in vivo in both mouse peritonitis and dermal inflammation; enhances macrophage phagocytosis and efferocytosis.

Major β-oxidation product resulting from peroxisomal metabolism of 12(S)-HETE

A major metabolite of PGD2 found in human and mouse urine at levels of approximately 1.5 and 8.1 ng/mg creatinine, respectively.

A minor CYP450 metabolite of arachidonic acid that stimulates vasodilation of rabbit kidney.

A non-enzymatic hydrolysis product of LTA4 with reduced activity compared to LTB4; also produced by oxidative decomposition of CysLTs such as LTC4 in the presence of myeloperoxidase and hypochlorous acid.

An isotopically enriched form of a PUFA with carbon-13 occurring at positions 1, 2, 3, 4, and 5; used to study metabolic processes related to arachidonic acid by means of mass spectrometry.

An EpEDE acid formed from DGLA, either by a strong oxidizing agent or by cytochrome P450 epoxygenases; biological properties are poorly understood.

Biosynthesis of LTA3 occurs from 5,8,11-eicosatrienoic acid via the 5-LO pathway{689} and it is the putative intermediate in the biosynthesis of 3-series leukotrienes. LTA3 as a free acid is highly unstable. The methyl ester is stable and can be readily hydrolyzed to the free acid as needed.

A potential metabolite of PGD2, presumably produced from the known metabolite 13,14-dihydro-15-keto PGD2.

One of the six monohydroxy fatty acids produced by the non-enzymatic oxidation of arachidonic acid.

An internal standard for quantification of 13,14-dihydro-15 (R,S)-hydroxy-16,16-difluoro-Prostaglandin E1, a metabolite of a bicyclic PGE1 derivative used in the treatment of chronic constipation, by GC- or LC-mass spectrometry (MS).

An analog of (±)14(15)-EpEDE with greater lipid solubility than the free base.

A proposed anti-inflammatory EPA metabolite that has been shown to promote inflammatory resolution in numerous disease models, including experimental colitis, asthma, atherosclerosis, type 2 diabetes, and HSV-1-induced stromal keratitis.

A dehydration product of tetranor-PGEM that can be measured as a surrogate for tetranor-PGEM levels in urine.

15-OxoETE is produced by oxidation of the 15-hydroxyl of 15-HETE. Whether this is a major pathway of 15-HETE metabolism is yet to be clearly established.